Basic & Clinical Medicine ›› 2024, Vol. 44 ›› Issue (3): 393-397.doi: 10.16352/j.issn.1001-6325.2024.03.0393
• Mini Reviews • Previous Articles Next Articles
NAN Lu1, GUO Menjie1, GAO Yanan1, JIA Hongyan2*
Received:
2023-10-17
Revised:
2023-12-27
Online:
2024-03-05
Published:
2024-02-22
Contact:
*:swallow_jhy@163.com
CLC Number:
NAN Lu, GUO Menjie, GAO Yanan, JIA Hongyan. Research progress on the mechanism of annexin A family members in breast cancer[J]. Basic & Clinical Medicine, 2024, 44(3): 393-397.
[1] | Li N, Xi Y, Du H, et al. Annexin A4 is dispensable for hair cell development and function[J]. Front Cell Dev Biol, 2021, 9: 680155. doi:10.3389/fcell.2021.680155. |
[2] | Hu Z, Li L, Zhu B, et al. Annexin A5 is essential for PKCθtranslocation during T-cell activation[J]. J Biol Chem, 2020, 295: 14214-14221. |
[3] | Yu ZZ, Liu YY, Zhu W, et al. ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers[J].J Immunother Cancer,2023,11:e006345. doi:10.1136/jitc-2022-006345. |
[4] | Głowacka A, Bieganowski P, Jurewicz E, et al. Regula-tion of S100A10 gene expression[J]. Biomolecules,2021,11:974.doi:10.3390/biom11070974. |
[5] | Liu J, Wang H, Zheng M, et al. p53 and ANXA4/NF-κB p50 complexes regulate cell proliferation, apoptosis and tumor progression in ovarian clear cell carcinoma[J].Int J Mol Med, 2020,46:2102-2114. |
[6] | Scala MC, Di Micco S, Lanzillotta D, et al. Overcome chemoresistance: biophysical and structural analysis of synthetic Fhit-derived peptides[J]. Front Mol Biosci, 2021,8:715263. doi:10.3389/fmolb.2021.715263. |
[7] | Guo Z, Guo A, Zhou C. Breast cancer stem cell-derived ANXA6-containing exosomes sustain paclitaxel resistance and cancer aggressiveness in breast cancer[J]. Front Cell Dev Biol, 2021, 9: 718721. doi:10.3389/fcell.2021.718721. |
[8] | Song L, Li H, Ma RR, et al. E2F1-initiated transcription of PRSS22 promotes breast cancer metastasis by cleaving ANXA1 and activating FPR2/ERK signaling pathway[J]. Cell Death Dis, 2022, 13: 982. doi:10.1038/s41419-022-05414-3. |
[9] | Tang L, Chen Y, Chen H, et al. DCST1-AS1 promotes TGF-β-induced epithelial-mesenchymal transition and enhances chemoresistance in triple-negative breast cancer Cells via ANXA1[J]. Front Oncol, 2020, 10: 280. doi:10.3389/fonc.2020.00280. |
[10] | Long Y, Chong T, Lyu X, et al. FOXD1-dependent RalA-ANXA2-Src complex promotes CTC formation in breast cancer[J].J Exp Clin Cancer Res,2022,41:301.doi:10.1186/s13046-022-02504-0. |
[11] | Fan Y, Si W, Ji W, et al. Rack1 mediates tyrosine phosphorylation of Anxa2 by Src and promotes invasion and metastasis in drug-resistant breast cancer cells[J]. Breast Cancer Res, 2019, 21: 66. doi:10.1186/s13058-019-1147-7. |
[12] | Strand E, Hollås H, Sakya SA, et al. Annexin A2 binds the internal ribosomal entry site of c-myc mRNA and regulates its translation[J]. RNA Biol, 2021,18: 337-354. |
[13] | Du R, Liu B, Zhou L, et al. Downregulation of annexin A3 inhibits tumor metastasis and decreases drug resistance in breast cancer[J]. Cell Death Dis,2018, 9: 126. doi:10.1038/s41419-017-0143-z. |
[14] | Kim JY, Jung EJ, Park HJ, et al. Tumor-suppressing effect of silencing of annexin A3 expression in breast cancer[J]. Clin Breast Cancer, 2018, 18: e713-e719. |
[15] | Kim JY, Jung EJ, Kim JM, et al. miR-221 and miR-222 regulate cell cycle progression and affect chemosensitivity in breast cancer by targeting ANXA3[J].Exp Ther Med,2023,25:127. doi:10.3892/etm.2023.11826. |
[16] | Li L, Zhang R, Liu Y, et al. ANXA4 activates JAK-STAT3 signaling by interacting with ANXA1 in basal-Like breast cancer[J].DNA Cell Biol, 2020, 39: 1649-1656. |
[17] | Hein T, Krammer PH, Weyd H. Molecular analysis of Annexin expression in cancer[J]. BMC cancer, 2022, 22: 994. doi:10.1186/s12885-022-10075-8. |
[18] | Kang TH, Park JH, Yang A, et al. Annexin A5 as an immune checkpoint inhibitor and tumor-homing molecule for cancer treatment[J].Nat Commun,2020,11:1137. doi:10.1038/s41467-020-14821-z. |
[19] | Hoque M, Elmaghrabi YA, Köse M, et al. Annexin A6 improves anti-migratory and anti-invasive properties of tyrosine kinase inhibitors in EGFR overexpressing human squamous epithelial cells[J]. FEBS J, 2020, 287: 2961-2978. |
[20] | Sakwe AM, Koumangoye R, Guillory B, et al. Annexin A6 contributes to the invasiveness of breast carcinoma cells by influencing the organization and localization of functional focal adhesions[J]. Exp Cell Res, 2011, 317: 823-837. |
[21] | Li T, Tao Z, Zhu Y, et al. Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer[J]. Cell Death Dis, 2021, 12: 684.doi:10.1038/s41419-021-03963-7. |
[22] | Williams SD, Smith TM, Stewart LV, et al. Hypoxia-inducible expression of annexin A6 enhances the resistance of triple-negative breast cancer cells to EGFR and AR antagonists[J]. Cells, 2022, 11: 3007.doi:10.3390/cells11193007. |
[23] | Rossetti S, Sacchi N. 3D mammary epithelial cell models: a goldmine of DCIS biomarkers and morphogene-tic mechanisms[J]. Cancers, 2019, 11: 130. doi:10.3390/cancers11020130. |
[24] | 田焕娜,吴雪艳,王小杰.敲低膜联蛋白A7对乳腺癌MCF-7细胞凋亡的影响[J]. 承德医学院学报, 2015: 193-195. |
[25] | Wang Z, Zhou X, Deng X, et al. miR-186-ANXA9 signaling inhibits tumorigenesis in breast cancer[J]. Front Oncol, 2023, 13: 1166666. doi:10.3389/fonc.2023.1166666. |
[1] | SU Lingfeng, WANG Huxia, WANG Yanfeng, SONG Zhangjun. Impact of chronic stress on the development of breast cancer [J]. Basic & Clinical Medicine, 2024, 44(9): 1303-1307. |
[2] | XIA Yujia, YANG Zhenli, DAI Di, LIU Yuqin. Culture and characterization of breast cancer organoids [J]. Basic & Clinical Medicine, 2024, 44(9): 1223-1228. |
[3] | LU Kai, LU Jianju, GUO Wenli, HUANG Jianqi, LI Zhihua. lncRNA VIM-AS5 expression and its effect on proliferation and migration of human breast cancer cell lines [J]. Basic & Clinical Medicine, 2024, 44(4): 447-453. |
[4] | Yiheliman·MAIMAITI, CAO Yanzhen, WANG Cuicui, YUE Na, LIANG Liping. Correlation between PIK3CA mutation and clinicopathological features and prognosis of breast cancer [J]. Basic & Clinical Medicine, 2024, 44(3): 303-307. |
[5] | LI Jiangli, SUN Jing, TANG Yijun, GUO Junlan, CHEN Bo, GUO Shengnan. Circ-DDX5 inhibits the proliferation and invasion of human breast cancer cell lines by targeting miR-3940 [J]. Basic & Clinical Medicine, 2024, 44(1): 1-7. |
[6] | CHEN Ning, PENG Tianying, ZHANG Weimiao, GAO Yanuo, LI Xuan, YAN Caizhen, LI Junxia. Synergistic pro-apoptotic effect of triptolide combined with doxorubicin in human breast cancer cell line MCF-7 [J]. Basic & Clinical Medicine, 2023, 43(8): 1186-1192. |
[7] | WANG Jihui, CAO Jilie, ZHANG Lijun, ZHANG Jun, LU Wenbao. TARBP2 promotes human breast cancer cell metastasis by degrading AKAP12 transcript [J]. Basic & Clinical Medicine, 2023, 43(8): 1259-1264. |
[8] | TANG Yijun, WANG Wenlong, LI Jiangli, YANG Huan, SUN Jing. LncRNA RP11-686D22.10 is related with the survival of breast cancer patients, affects the proliferation, invasion of breast cancer cell lines [J]. Basic & Clinical Medicine, 2023, 43(7): 1023-1029. |
[9] | ZHANG Yanping, YAO Liuxu, DING Qiannan, HUANG Zeyong, LI Yuhong, HUANG Suqin. Influencing factors and the clinical significance of tumorigenesis rate in PDX model of colorectal cancer [J]. Basic & Clinical Medicine, 2023, 43(4): 596-602. |
[10] | YANG Liangquan, YU Miao, JIANG Qian, ZHANG Minghui, YANG Haisong. miR-504 regulates proteasome activator and inhibits the proliferation and migration of breast cancer cell line MCF-7 [J]. Basic & Clinical Medicine, 2023, 43(1): 95-101. |
[11] | WANG Qun, LI Xin, MA Jun, LI Wanming. Imaging of breast cancer targeted by the nucleic acid aptamer W3-quantum dots [J]. Basic & Clinical Medicine, 2023, 43(1): 76-82. |
[12] | ZHANG Xiao-lei, LIU Jing, LI Chao-ping. Circ_0032821 is involved in sorafenib's inhibition of the proliferation, migration and invasion of breast cancer cell line T47D [J]. Basic & Clinical Medicine, 2022, 42(9): 1350-1354. |
[13] | WANG Zi-yuan, DUAN Zhao-jun, LUO Yun-ping. Establishment and validation of lung-specific metastatic cell subline of mouse breast cancer [J]. Basic & Clinical Medicine, 2022, 42(7): 1083-1091. |
[14] | HAN Xue-ying, CUI Feng, LI Jun. Deleted in breast cancer 1(DBC1) affects the sensitivity of breast cancer cell lines to etoposide [J]. Basic & Clinical Medicine, 2022, 42(7): 1060-1066. |
[15] | KANG You-li, ZHAO Dan, DU Wen-jing, LI Li. SIRT5 promotes the proliferation of human breast cancer cells by regulating the succinylation of ALDH5A1 [J]. Basic & Clinical Medicine, 2022, 42(7): 1099-1107. |
Viewed | ||||||||||||||||||||||||||||||||||||||||||||||||||
Full text 170
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Abstract 168
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||